Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.

Schüpbach, Michael; Tonder, Lisa; Schnitzler, Alfons; Krack, Paul; Rau, Joern; Hartmann, Andreas; Hälbig, Thomas D; Pineau, Fanny; Falk, Andrea; Paschen, Laura; Paschen, Stephen; Volkmann, Jens; Dafsari, Haidar S; Barbe, Michael T; Fink, Gereon R; Kühn, Andrea; Kupsch, Andreas; Schneider, Gerd-H; Seigneuret, Eric; Fraix, Valerie; ... (2019). Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology, 92(10), e1109-e1120. American Academy of Neurology 10.1212/WNL.0000000000007037

Preview

Text e1109.full.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (627kB) | Preview

OBJECTIVE

To investigate predictors for improvement of disease-specific quality of life (QOL) after deep brain stimulation (DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications.

METHODS

We performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up with disease-specific QOL (39-item Parkinson's Disease Questionnaire summary index [PDQ-39-SI]) as the primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of motor complications, and disease severity measured at baseline with the Unified Parkinson's Disease Rating Scale (UPDRS) (UPDRS-III "off" and "on" medications, UPDRS-IV) were conducted to determine predictors of change in PDQ-39-SI.

RESULTS

PDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups (p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months. No correlation was found for any of the other baseline characteristics analyzed in either treatment group.

CONCLUSION

Impaired QOL as subjectively evaluated by the patient is the most important predictor of benefit in patients with PD and early motor complications, fulfilling objective gold standard inclusion criteria for STN-DBS. Our results prompt systematically including evaluation of disease-specific QOL when selecting patients with PD for STN-DBS.

CLINICALTRIALSGOV IDENTIFIER

NCT00354133.

Interest & Impact

Downloads

275 since deposited on 18 Nov 2019
60 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item